Email this page

Print this page

Report

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

Melarkode S. Ramakrishnan, Anand Eswariah, Tania Crombet, Patricia Piedra, Giselle Saurez, Harish Iyer and A.S. Arvind

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR).  Clinical trials are ongoing globally to evaluate nimotuzumab in different  indications.  Nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in different countries.  This review focuses on the unique functional characteristics of nimotuzumab.  Also, it discusses the safety and efficacy data obtained from the Phase IIb clinical trial conducted in India in SCCHN.  Post Marketing Surveillance data from Cuba for the use of nimotuzumab in pediatric and adult glioma is also discussed.  Overall, nimotuzumab has immense therapeutic potential in cancers of epithelial origin.

Authors

Melarkode S. Ramakrishnan Corresponding author: ramakrishnan.melarkode@biocon.com

Biocon Limited

Anand Eswariah

Clinigene International Limited

Tania Crombet

Center for Molecular Immunology (CIM), Cuba

Patricia Piedra

Center for Molecular Immunology (CIM), Cuba

Giselle Saurez

Center for Molecular Immunology (CIM), Cuba

Harish Iyer

Biocon Limited

A.S. Arvind

Clinigene International Limited

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.